My work focuses on the prevention of vascular disease. A major aim of mine is to improve outcome after stroke. We can test this by assessing whether individualised management plans provided to people with stroke will improve risk factors. Proper risk factor management reduces the risk of stroke recurrence. I also aim to reduce the burden of vascular disease in disadvantaged settings by finding out what risk factors are important in the development of these diseases in people living in poverty.
Developing And Implementing Proven Treatments And Systems Of Care In Stroke
Funder
National Health and Medical Research Council
Funding Amount
$873,684.00
Summary
This fellowship will allow me to continue undertaking large-scale, multicentre, national and international, randomised controlled trials and population-based epidemiological studies focussed on the prevention and managment of acute stroke and other aspects of cardiovascular disease related to ageing populations. Much of my research is focussed on research and health policy of populations in Asia, particularly China, where i have had a sustained program of collaborative research over 10 years.
Craig Anderson is a clinician-scientist, with specialist training in neurology and geriatrics, and an internationally-recognised epidemiologist and clinical trialist researcher. His work is dedicated to generating the highest quality evidence to improve the prevention and treatment of stroke and other neurological diseases related to ageing.
Venoms To Drugs: Translating Venom Peptides Into Human Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$774,540.00
Summary
Many disorders of the nervous system, including chronic pain, epilepsy and the neuronal degeneration suffered following a stroke, result from malfunction of channels that ferry ions across neuronal cell membranes. There are very few drugs available for treating these disorders and they often have debilitating side-effects. We are developing potent and selective modulators of these ion channels as the next-generation of safe and effective analgesic, anti-epileptic, and neuroprotective drugs.
Stroke is a devastating disease causing mortality and morbidity on a massive scale, and which still has no treatment besides a clot-buster that cannot be used in 90% of patients. This research should provide a better understanding of stroke pathology and identify new therapeutic directions. It will elucidate an unappreciated but crucial role of specific immune cells in brain injury after stroke, and hopefully lead to new ways to limit brain injury and promote recovery from stroke.
Affordable And Scaleable New Strategies For Cardiovascular Disease Control
Funder
National Health and Medical Research Council
Funding Amount
$609,384.00
Summary
This Fellowship will support Professor Anthony Rodgers to continue a track record of excellence in health research, public-private partnerships and innovation. He has led landmark cardiovascular trials and was Principal Author of the WHO World Health Report. He plans a program of research on new combination cardiovascular medicines ('polypills'). Polypill trials that Professor Rodgers initiated have recently shown improved clinical outcomes, patient acceptability, quality of life and cost saving ....This Fellowship will support Professor Anthony Rodgers to continue a track record of excellence in health research, public-private partnerships and innovation. He has led landmark cardiovascular trials and was Principal Author of the WHO World Health Report. He plans a program of research on new combination cardiovascular medicines ('polypills'). Polypill trials that Professor Rodgers initiated have recently shown improved clinical outcomes, patient acceptability, quality of life and cost savings.Read moreRead less
The mechanisms regulating expression and function of surface receptors on blood platelets are critical for understanding cardiovascular diseases involving aberrant platelet function, not only thrombotic diseases such as heart attack or stroke, but other pathology involving platelets including coagulopathy and autoimmune thrombocytopenia caused by anti-platelet antibodies. Improved diagnosis and therapeutic targeting of platelet-specific receptors mediating arterial thrombosis can save many lives ....The mechanisms regulating expression and function of surface receptors on blood platelets are critical for understanding cardiovascular diseases involving aberrant platelet function, not only thrombotic diseases such as heart attack or stroke, but other pathology involving platelets including coagulopathy and autoimmune thrombocytopenia caused by anti-platelet antibodies. Improved diagnosis and therapeutic targeting of platelet-specific receptors mediating arterial thrombosis can save many lives given the prevalence and severity of disease.Read moreRead less
We aim to grow body tissues for surgery, including heart muscle, liver and pancreatic islets (for diabetes) and will investigate using stem cells to repair the brain after stroke. We will attempt to boost the expansion of blood vessels in growing tissues using molecular tools we have found crucial for cell signaling. In growing heart tissues and in stroke we will improve drugs that might boost the potential of stem cells to regenerate damaged tissues
Exploiting Existing Data Sources To Improve The Prevention And Treatment Of Cardiovascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$772,490.00
Summary
My program of research exploits several large databases to answer important issues in the prevention and treatment of cardiovascular disease (CVD), which makes a huge contribution to the burden of illness and premature mortality in Australia. An underlying aim is to provide the evidence base to facilitate improvement of the existing CVD risk assessment guidelines in Australia, for better targeting of clinical advice and treatment.
Investigating A Potential New Treatment For Stroke
Funder
National Health and Medical Research Council
Funding Amount
$878,522.00
Summary
Blood clots blocking blood flow to the brain (stroke) are a major cause of death and disability. Safety concerns limit approved therapies to a small subset of patients, highlighting an urgent need for safer, more effective drugs. Our studies show that inhibitors of the enzyme PI3Kbeta increase blood clot permeability, increasing clot ‘dissolvability’, without increased bleeding. This raises the possibility that PI3Kbeta inhibitors may represent a safe and effective adjuvant therapy for stroke.